Phase 2 study for people with Epilepsy

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Encoded Therapeutics
Registry number NCT05419492
Started 14 May 2024 Today 16 October 2026 Estimated completion 1 January 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
The Royal Children's Hospital Melbourne Australia Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 6 Months to 17 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 47

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participant must be aged between ≥6 months and \<36 months in Part 1A, ≥48 months and \<18 years in Part 1B, ≥6 months and \<48 months in Part 2.

* Participant must have a predicted loss of function pathogenic or likely pathogenic SCN1A variant.

* Participant must have experienced their first seizure between the ages of 3 and 15 months.

* Participant must have a clinical diagnosis of Dravet syndrome or the treating clinician must have a high clinical suspicion of a diagnosis of Dravet syndrome.

* Participant is receiving at least one prophylactic antiseizure medication.

Exclusion Criteria:

* Participant has another genetic mutation or clinical comorbidity which could potentially confound the typical Dravet phenotype.

* Participant has a known central nervous system structural and/or vascular abnormality (indicated by an MRI or CT scan of the brain).

* Participant has an abnormality that may interfere with CSF distribution and/or has an existing ventriculoperitoneal shunt.

* Participant has received sodium channel blockers during the Pre-Dosing Seizure Period.

* Participant has experienced seizure freedom for a period of 4 consecutive weeks within the 90-day period prior to informed consent.

* Participant has previously received gene or cell therapy.

* Participant is currently enrolled in a clinical trial or receiving an investigational therapy.

* Participant has clinically significant underlying liver disease.

Dates on the record

Started 14 May 2024
Estimated completion 1 January 2028
Registry last updated 22 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 22 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.